2024年美国临床肿瘤学会亮点。
Highlights of ASCO 2024.
作者信息
Neugut Alfred I, Bates Susan E
机构信息
Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Department of Epidemiology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, United States.
出版信息
Oncologist. 2024 Nov 4;29(11):913-917. doi: 10.1093/oncolo/oyae250.
Abstract
Highlights from the ASCO annual meeting are presented.
摘要
本文展示了美国临床肿瘤学会年会的重点内容。
相似文献
1
Highlights of ASCO 2024.2024年美国临床肿瘤学会亮点。
Oncologist. 2024 Nov 4;29(11):913-917. doi: 10.1093/oncolo/oyae250.
2
A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study.一项通过模拟研究比较使用风险比点估计或置信区间界限评估时间事件终点附加获益评估方法的研究。
Med Decis Making. 2024 May;44(4):365-379. doi: 10.1177/0272989X241239928. Epub 2024 May 9.
3
Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting.胃肠道癌症的最新进展和突破：2022 年美国临床肿瘤学会（ASCO）胃肠道会议亮点。
J Gastrointest Cancer. 2023 Jun;54(2):672-676. doi: 10.1007/s12029-022-00849-5. Epub 2022 Jul 19.
4
[ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003].[2003年美国临床肿瘤学会年会更新——第39届美国临床肿瘤学会年会（ASCO 2003）亮点]
Z Gastroenterol. 2003 Oct;41(10):1039-45. doi: 10.1055/s-2003-42922.
5
2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Prostate Cancer.2019年美国临床肿瘤学会年会高级从业者要点：前列腺癌
J Adv Pract Oncol. 2019 Aug;10(6):547-553. doi: 10.6004/jadpro.2019.10.6.3. Epub 2019 Aug 1.
6
2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Gastrointestinal Cancer.2019年美国临床肿瘤学会年会高级从业者重点关注内容：胃肠道癌症
J Adv Pract Oncol. 2019 Aug;10(6):536-544. doi: 10.6004/jadpro.2019.10.6.2. Epub 2019 Aug 1.
7
[ASCO update -- highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004].[美国临床肿瘤学会更新——美国临床肿瘤学会第40届会议/2004年美国临床肿瘤学会会议亮点]
Z Gastroenterol. 2004 Dec;42(12):1416-24. doi: 10.1055/s-2004-813819.
8
Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting.2022年美国临床肿瘤学会年会肾癌研究亮点
Kidney Cancer J. 2022 Jun;20(2):61-64.
9
2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Gynecologic Cancers.2019年美国临床肿瘤学会年会高级从业者亮点：妇科癌症
J Adv Pract Oncol. 2019 Aug;10(6):560-564. doi: 10.6004/jadpro.2019.10.6.5. Epub 2019 Aug 1.
10
2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Issues in Oncology.2019年美国临床肿瘤学会年会高级从业者要点：肿瘤学问题
J Adv Pract Oncol. 2019 Aug;10(6):610-616. doi: 10.6004/jadpro.2019.10.6.11. Epub 2019 Aug 1.
本文引用的文献
1
Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.奥希替尼用于 III 期 - 突变型 NSCLC 放化疗后的治疗。
N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2.
2
Stepped Palliative Care for Patients With Advanced Lung Cancer: A Randomized Clinical Trial.阶梯式姑息治疗对晚期肺癌患者的影响：一项随机临床试验。
JAMA. 2024 Aug 13;332(6):471-481. doi: 10.1001/jama.2024.10398.
3
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.阿西替尼治疗新诊断的慢性髓性白血病。
N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31.
4
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。
J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.
5
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.ASCENT 试验：在 III 期 EGFR 突变 NSCLC 中，阿法替尼诱导和巩固治疗联合或不联合手术与放化疗的 II 期研究。
Oncologist. 2024 Jul 5;29(7):609-618. doi: 10.1093/oncolo/oyae107.
6
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.特泊替尼治疗既往治疗的小细胞肺癌患者。
N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20.
7
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.纳武利尤单抗辅助治疗食管或胃食管结合部癌。
N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
8
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
9
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
10
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).ESOPEC：一项前瞻性随机对照多中心III期试验，比较围手术期化疗（FLOT方案）与新辅助放化疗（CROSS方案）用于食管癌患者（NCT02509286）。
BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.
Zotero 插件